The IMpower 150 study that explored atezolizumab plus chemotherapy and bevacizumab regimen showed the prolonged survival in non-squamous NSCLC patients, irrespective of EGFR mutation status.13,14 Evidence from this study supported further investigations of chemoimmunotherapy plus bevacizumab in treatment-naïve NSCLC that progressed on prior EGFR-TKIs, regardless of EGFR mutation status. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.